125 related articles for article (PubMed ID: 17580370)
1. FDA notifications. FDA issues public health advisory about ESAs.
AIDS Alert; 2007 May; 22(5):57-8. PubMed ID: 17580370
[No Abstract] [Full Text] [Related]
2. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
3. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
Brower V
J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
[No Abstract] [Full Text] [Related]
4. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
5. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
6. FDA panel scrutinizes safety of anti-anemia drugs.
Randal J
J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
[No Abstract] [Full Text] [Related]
7. ESAs further restricted, but debate continues.
Brower V
J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
[No Abstract] [Full Text] [Related]
8. FDA approves Epoetin Alfa use for AZT patients.
Nephrol News Issues; 1991 Apr; 5(4):11. PubMed ID: 1961277
[No Abstract] [Full Text] [Related]
9. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
10. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
Khuri FR
N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
[No Abstract] [Full Text] [Related]
11. Safety concerns for two big anemia drugs.
Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
[No Abstract] [Full Text] [Related]
12. The FDA, stocks, black boxes and ESAs.
Spry L
Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124
[No Abstract] [Full Text] [Related]
13. FDA notifications. Fixed dose ART approved by FDA.
AIDS Alert; 2011 Mar; 26(3):35-6. PubMed ID: 21539043
[No Abstract] [Full Text] [Related]
14. Erythropoietin for zidovudine-induced anemia.
N Engl J Med; 1990 Oct; 323(15):1069-70. PubMed ID: 2215568
[No Abstract] [Full Text] [Related]
15. Biosimilar epoetins.
Macdougall IC
Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
[No Abstract] [Full Text] [Related]
16. FDA approves Eprex for anemia related to AIDS.
Nurse Pract; 1989 Sep; 14(9):6. PubMed ID: 2779868
[No Abstract] [Full Text] [Related]
17. Recombinant erythropoietin for zidovudine-induced anemia in AIDS.
Kuehl AK; Noormohamed SE
Ann Pharmacother; 1995; 29(7-8):778-9. PubMed ID: 8520096
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alpha approved for anemic AIDS patients.
J Am Osteopath Assoc; 1991 Jun; 91(6):538. PubMed ID: 1874651
[No Abstract] [Full Text] [Related]
19. FDA notifications. FDA tentatively approves fixed-dose lamivudine/zidovudine.
AIDS Alert; 2010 Dec; 25(12):142-3. PubMed ID: 21328815
[No Abstract] [Full Text] [Related]
20. FDA likely to further restrict erythropoietin use for cancer patients.
Fox JL
Nat Biotechnol; 2007 Jun; 25(6):607-8. PubMed ID: 17557084
[No Abstract] [Full Text] [Related]
[Next] [New Search]
